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Abstract The application of the Fluorosome technique to test
drug delivery systems is described. Fluorosomes, egg phospha-
tidylcholine liposomes with bilayer embedded fluorophores, were
employed to investigate the ability of sonicated small unilamellar
vesicles (sSUV) and L-cyclodextrins (L-CD) to deliver drugs into
or extract drugs from the fluorosome’s phospholipid bilayer. The
addition of phloretin to a fluorosome suspension resulted in
fluorescence reduction reflecting phloretin entering the bilayer
and quenching fluorophore fluorescence. Subsequent addition of
sSUV to phloretin pretreated fluorosomes showed an increase in
fluorescence reflecting phloretin extraction from the fluorosome
membrane. Sequential additions of L-estradiol loaded L-CD to
fluorosomes as well as the addition of L-estradiol alone resulted
in fluorescence reduction due to L-estradiol insertion into the
membrane. Further addition of pure L-CD resulted in a
fluorescence increase indicating L-estradiol extraction from the
fluorosome membrane. ß 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
In the past, the major focus in drug research has been the
development of drugs with new or increasingly potent biolog-
ical activities. While this is still the case, the development of
new formulations emphasizing drug delivery systems is be-
coming of increasing importance in enhancing drug e¡ective-
ness and safety [1,2]. Free doxorubicin, an antibiotic and anti-
tumor drug, for example, is pumped out of multidrug resistant
cancer cells by P-glycoprotein. Doxorubicin loaded nanopar-
ticles are able to adsorb onto the tumor cell and progressively
release the encapsulated drug, the high local drug concentra-
tion gradient favoring the intracellular penetration of doxoru-
bicin [3].
Drug delivery systems can be formed variously from lipids,
carbohydrates, proteins, or synthetic polymer systems in a
large variety of con¢gurations [1,2,4^6], for example, drug
entrapment in vesicles or liposomes [1,5,7]. Moreover, lipid
systems such as sonicated small unilamellar vesicles (sSUV)
are used to extract cholesterol from lysosomes [8]. Cyclodex-
trins (CD), water soluble cyclic oligosaccharides containing a
minimum of six D-glucopyranose units with hydrophobic cav-
ities [9], are also used as drug delivery systems in pharmaceut-
ical applications [4]. L-CD can be used to manipulate and
mediate cellular cholesterol content [10^14] as well as in re-
moving cholesterol from homogenized milk [15].
Lipid bilayer membranes are key objects in drug research
with regard to the interaction of drugs with membrane bound
receptors, drug targeting, penetration, and permeation of cell
membranes, and the use of liposomes in micro-encapsulation
technologies for drug delivery [6,16].
In view of the increasing rate of development in the area of
drug delivery, a rapid in vitro system to investigate the ability
of a drug delivery vehicle to deliver drugs into a membrane
bilayer would be bene¢cial. In previous studies, we described
a rapid in vitro £uorescent assay, the Fluorosome technique,
for measuring the entry rates of molecules into membranes
[17,18]. Fluorosomes are small unilamellar vesicles, with a
£uorescent dye embedded in their bilayers. The decrease of
£uorescence induced by the presence of drug molecules in the
bilayer is used to measure the bilayer entry of such molecules.
It might be expected that the extraction of drug molecules
from the membrane should result in a £uorescence increase
and therefore monitor bilayer exit after initial insertion. The
Fluorosome technique requires only nanomol quantities of
test molecules and can measure a wide variety of membrane
entry rates. In this paper we demonstrate the potential of the
Fluorosome technique as an empirical in vitro method to
characterize the entry of a drug from a carrier moiety into a
membrane bilayer as well as drug removal from a membrane
by a carrier vehicle. For this purpose we employed sSUV and
L-CD as model carrier vehicles.
2. Materials and methods
2.1. Materials
Egg phosphatidylcholine (egg PC, 26.3 mM, in chloroform) was
purchased from Avanti Polar Lipids (Alabaster, AL, USA). L-DPH-
HPC (2-(3-(diphenylhexatrienyl)propanoyl)-1-hexadecanoyl-sn-glyc-
ero-3-phosphocholine) and NBD-C6-HPC (2-(6-(7-nitrobenz-2-oxa-
1,3-diazol-4-yl)amino)hexanoyl-1-hexadecanoyl-sn-glycero-3-phospho-
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choline) (Molecular Probes, Eugene, OR, USA) were dissolved in
chloroform (HPLC-grade, Sigma-Aldrich, Milwaukee, WI, USA) to
concentrations of 355 WM and 1.7 mM, respectively. Phloretin and L-
estradiol (Sigma, St. Louis, MO, USA) were dissolved to 10 mM and
40 mM, respectively in dimethyl sulfoxide (DMSO, ICN Biomedicals
Inc., Aurora, OH, USA) and were stored in brown bottles at 277 K.
10 mM Tris^HCl pH 7.4 bu¡er was made of ultrapure tris(hydrox-
ymethyl)aminomethane (Tris, T.J. Baker, Philipsburg, NJ, USA), ¢l-
tered through 0.2 Wm GTTP Isopore1 membranes (Millipore, Bed-
ford, MA, USA) to prevent dust and stored at 277 K.
2.2. Preparation of L-CD solutions
Solutions of 10 mM and 13.3 mM L-CD (Sigma) were prepared in
ultrapure water (pH 5.6, conductance of 18.2 M6cm, Photronix,
Medway, MA, USA) immediately before use. L-Estradiol loaded L-
CD were prepared by mixing 300 Wl of a 13.3 mM L-CD solution in
ultrapure water with 20 Wl of a 40 mM L-estradiol solution in DMSO
together with an additional 200 Wl DMSO and stirred overnight. The
L-CD/L-estradiol solution was used within 12 h of preparation.
2.3. Preparation of sSUV
sSUV were prepared by adding 300 Wl of a 26.3 mM egg PC/chlo-
roform solution into a 6 ml £at bottom glass tube, evaporating the
chloroform under a nitrogen £ow and placing the resulting ¢lm under
vacuum (0.1 mm Hg) for 3 h. The resulting ¢lm was hydrated with 10
mM Tris bu¡er pH 7.4 for 5 min and agitated to form multilamellar
vesicles (MLV). 500 Wl of the MLV suspension was transferred to
another 6 ml glass tube, placed in ice water to prevent overheating
during sonication and sonicated using the sonicator microtip (Sonic
Dismembrator model 300, Fisher Scienti¢c, Bohemia, NY, USA) at
35% full power for 25 min until a clear sSUV solution was obtained.
To avoid membrane fusion, the sSUV were stored at 277 K and used
within 1 day.
2.4. Preparation of £uorosomes
L-DPH-HPC/egg PC £uorosomes: chloroform solutions of 300 Wl
26.3 mM egg PC and 10.7 Wl 355 WM L-DPH-HPC were pipetted into
a glass tube (giving a 0.05 mol% £uorescence dye to phospholipid
ratio). NBD-C6-HPC/egg PC £uorosomes: chloroform solutions of
300 Wl 26.3 mM egg PC and 20 Wl 1.7 mM NBD-C6-HPC were
pipetted into a glass tube (resulting in a 0.43 mol% £uorescence dye
to phospholipid ratio). The organic solvent was evaporated under a
£ow of nitrogen. The resulting ¢lm was put under vacuum (0.1 mm
Hg) for 3 h and taken up in 600 Wl ultrapure water (NBD-C6-HPC
£uorosomes) or 600 Wl 10 mM Tris bu¡er pH 7.4 (L-DPH-HPC £uo-
rosomes). After 5 min the ¢lm was agitated to form MLV. Unilamel-
lar vesicles of a homogeneous size were formed by use of a membrane
extrusion device (Liposofast0, Avestin, Ottawa, ON, Canada). Using
this device the MLV were subjected to 31 passes through a polycar-
bonate ¢lter with 100 nm pores. Fluorosome size was con¢rmed by
photon correlation photometry to be tightly centered around 100 nm
(Coulter N4 submicron particle analyzer, Coulter Electronics, Hia-
leah, FL, USA). Approximately 500 Wl of the £uorosome solution
was diluted with water to a ¢nal volume of 100 ml. To avoid photo-
bleaching, all preparation steps were carried out under aluminum foil.
All £uorosome suspensions were stored in aluminum foil wrapped
bottles at 277 K and used within 1 week.
2.5. Fluorescence spectroscopy
Measurements were performed using 3 ml aliquots of £uorosome
suspension at 293 K in a FluoroMax II (SPEX, Edison, NJ, USA)
under intense stirring. Spectrophotometer settings for experiments
with L-DPH-HPC/egg PC £uorosomes were: excitation 356 nm, emis-
sion 428 nm, excitation slit bandpass 1 nm, emission slit bandpass
6 nm, and for the NBD-C6-HPC/egg PC £uorosomes: excitation 465
nm, emission 538 nm, excitation slit bandpass 1 nm, emission slit
bandpass 6 nm. The £uorescence emission of the £uorosomes was
monitored for a minimum 1000 s prior to the addition of drug solu-
tions to the cuvette to establish a baseline. A 10 Wl syringe (Hamilton,
Reno, NV, USA) with a custom made extra long needle was used to
add up to 5 Wl of the L-estradiol solution as well as the L-CD solution
to the NBD-C6-HPC/egg PC £uorosomes through an injection port
on the spectrophotometer. A pipettor (Pipetman0, Gilson, distributed
through Rainin, Woburn, MA, USA) was used to perform the experi-
ments with the L-DPH-HPC/egg PC £uorosomes. For this purpose,
the measuring chamber was protected against light by a custom made
lid. The addition of 5 Wl or less pure DMSO to the £uorosomes
showed no e¡ect on the £uorescence signal or on the £uorosome
size as determined by the Coulter submicron particle analyzer. Emis-
sion values were acquired every second to ensure a signi¢cant acqui-
sition of data points.
3. Results
3.1. Phloretin/sSUV system
Unilamellar egg PC vesicles with 0.05 mol% L-DPH-HPC
as £uorescent probe (L-DPH-HPC/egg PC £uorosomes) were
prepared and used to examine changes in £uorescence inten-
sity after the addition of phloretin and sSUV. The results are
presented in Fig. 1 as £uorescence vs. time graphs. Fig. 1A^D
shows the actual £uorescence intensities, while in Fig. 1E, a
summary of the previous frames is given for comparison pur-
poses.
Due to the photobleaching of L-DPH-HPC, baseline £uo-
rescence intensity decreases in the course of an experiment in
a non-linear manner (3% within the ¢rst 1000 s). In Fig. 1A,B,
circle-ended arrows indicate the addition of 0.5 Wl aliquots of
a 10 mM DMSO solution of phloretin (5 nmol phloretin) to a
£uorosome suspension. The additions of phloretin result in
rapid and large decreases in £uorescence intensity. Sequential
additions of sSUV to the £uorosome system (regular arrows)
after the initial addition of phloretin result in sequential in-
creases in £uorescence. In Fig. 1A, following an initial addi-
tion of two additions of sSUV, a second addition of phloretin
results again in a decrease in £uorescence.
Fig. 1C,D shows control experiments, demonstrating that
the addition of sSUV (2U8 Wl, Fig. 1C) or pure DMSO (2U1
Wl, Fig. 1D) to the £uorosome preparation results in no
change in £uorescence.
The normalized £uorescence compilation summarizing all
measurements (Fig. 1E) demonstrates that the same baselines
are obtained for the reference experiments with sSUV and
DMSO as well as for the phloretin experiments prior to the
addition of phloretin. The additions of 5 nmol phloretin to
individual £uorosome suspensions result in the same magni-
tude of £uorescence decrease. Additionally, £uorescence in-
creases equivalently for both experiments after additions of
8 Wl sSUV to the phloretin loaded £uorosome suspension.
3.2. L-Estradiol/L-CD-system
Unilamellar egg PC vesicles with 0.43 mol% NBD-C6-HPC
as £uorescence probe (NBD-C6-HPC/egg PC £uorosomes)
were prepared and used to examine the changes in £uores-
cence intensity after the addition of L-estradiol and L-CD.
The results are presented in Fig. 2 as £uorescence vs. time
graphs. Fig. 2A^C are actual measured £uorescence inten-
sities, while Fig. 2D, a compilation of all NBD-C6-HPC/egg
PC £uorosome experiments, is given for comparison purposes.
Due to the photobleaching of NBD-C6-HPC, baseline £uo-
rescence intensity decreases in the course of an experiment in
a non-linear manner (1% within the ¢rst 1000 s). In Fig. 2A,
the circle-ended arrow indicates the addition of 1 Wl of 40 mM
(40 nmol) L-estradiol as a DMSO solution to a £uorosome
suspension. The addition of L-estradiol results in a rapid and
large decrease in £uorescence intensity, which is reversed in
part by the two additions of 5 Wl of the L-CD solution indi-
cated by regular arrows.
Fig. 2B shows an experiment where L-CD preloaded with L-
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estradiol was added in aliquots (arrows) to a £uorosome sus-
pension to a ¢nal L-estradiol content of 40 nmol. All additions
resulted in decreases in £uorescence intensity. In Fig. 2C the
arrows indicate additions of pure L-CD solution, which lead
to no change in £uorescence intensity. Pure DMSO also re-
sults in no reduction of the £uorosome £uorescence (data not
shown).
Fig. 2D shows a composite plot of Fig. 2A^C with the
£uorescence normalized; it may be noted that the presence
Fig. 1. Fluorescence intensity vs. time resulting from phloretin inser-
tion into the membranes of L-DPH-HPC/egg PC £uorosomes and
its subsequent extraction by sSUV. A,B: Addition of 5 nmol phlore-
tin in DMSO (circle-ended arrows) results in a rapid decrease in
£uorescence reversed by subsequent applications of 8 Wl sSUV sus-
pension (normal arrows). Fluorosomes are sensitive to a second ad-
dition of phloretin even after sSUV addition (A). C,D: Control ad-
ditions (arrows) of 2U8 Wl sSUV (C) and 2U1 Wl DMSO (D) lead
to no change in £uorescence signal. E: Composite normalized £uo-
rescence for the previous panels.
Fig. 2. Fluorescence intensity vs. time resulting from L-estradiol in-
sertion into the membranes of NBD-C6-HPC/egg PC £uorosomes
and its subsequent extraction by L-CD. A: Addition of 40 nmol L-
estradiol as a DMSO solution (circled-ended arrow) results in a rap-
id decrease in £uorescence. Successive additions of 5 Wl L-CD solu-
tion (normal arrows) lead to progressive increases in £uorescence in-
tensity. B: Additions of preincubated L-CD and L-estradiol result in
decreases in £uorescence intensity. C: Control additions (arrows) of
untreated L-CD result in no signi¢cant change in £uorescence. D:
Composite normalized £uorescence for the previous panels. An
equal normalized £uorescence intensity obtains for the experiments
shown in A and B in which the ¢nal amounts of L-estradiol are the
same.
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of 40 nmol L-estradiol in a NBD-C6-HPC £uorosome suspen-
sion results in the same value of £uorescence in the presence
of approximately equivalent amounts of L-CD, regardless of
the manner the L-CD addition was made.
4. Discussion
We describe the use of the Fluorosome technique to inves-
tigate drug delivery or drug extraction from membrane bi-
layers using sSUV and L-CD. The previously published pro-
cedure for £uorosome preparation [17,18] was altered by
preparing an egg PC/£uorophore ¢lm prior to MLV forma-
tion, which enables the usage of complex £uorophores and
ensures complete incorporation of £uorophore molecules
into the membrane. The use of £uorosomes employing £uo-
rophores not covalently bound to anchor phospholipids is not
suitable for studies on drug delivery vehicles, since unbound
£uorophores can be extracted form the bilayer by drug deliv-
ery vehicles. The £uorosomes used in this study contained
either of two di¡erent £uorophores, L-DPH-HPC or NBD-
C6-HPC. These were chosen to demonstrate the versatility
of the Fluorosome technique for investigating a variety of
drugs or drug delivery vehicles, even in those cases where
the drug or drug delivery system possesses an intrinsic £uo-
rescence overlapping in wavelength that of a speci¢c £uoro-
phore. Other £uorophores, in addition to the two described in
this paper, can be used in the preparation of £uorosomes.
Our results using sSUV loaded with L-estradiol are similar
those of Noy and Xu [19] who used unilamellar egg PC
vesicles with 2 mol% NBD-DPPE as both acceptor and donor
vesicles to examine the transfer of retinol between model
membranes. Their system had the £uorophore anchored at
the headgroup region of the phospholipid bilayer. Thus the
retinol molecules were detected at the exterior hydrophilic
region of the model membrane, in contrast to our system
where the drugs are detected only after they enter the interior
of the bilayer itself.
Both £uorosome systems, L-DPH-HPC/egg PC and NBD-
C6-HPC/egg PC, show slowly decreasing £uorescence inten-
sities due to photobleaching of the £uorescence dyes, however
this gradual photobleaching does not obscure £uorescence
changes resulting from the insertion of phloretin and L-estra-
diol into the model membranes. Reference experiments with
pure DMSO as well as aqueous solutions as used for the
sSUV preparation and L-CD solution showed no e¡ect on
the £uorescence of the £uorosomes. L-CD solutions and
sSUV suspensions were also tested for their in£uence on £uo-
rosome £uorescence, both showing no e¡ect on the £uores-
cence signal.
L-DPH-HPC/egg PC £uorosomes were used to demonstrate
their ability to monitor the extraction of phloretin from mem-
brane bilayers by sSUV. The removal of phloretin by sSUV is
seen as a reversal of the £uorescence quenching initially
brought about by the entry of phloretin molecules into the
£uorosome membrane.
NBD-C6-HPC/egg PC £uorosomes were employed to dem-
onstrate their ability to monitor the extraction of L-estradiol
from membrane bilayers by L-CD. To demonstrate the ability
of £uorosomes to monitor drug transfer from drug delivery
systems into membrane bilayers, L-CD loaded with L-estradiol
was added to a £uorosome suspension. Sequential additions
of L-CD/L-estradiol resulted in a reduction of £uorescence
signal, as did the addition of L-estradiol alone. Normalized
£uorescence intensities were the same for a ¢nal amount of L-
estradiol of 40 nmol in both experiments, despite the manner
in which L-estradiol and L-CD were added to the £uorosome
suspension: the hormone inserted into the £uorosome mem-
brane and was extracted by L-CD in the ¢rst experiment, the
L-estradiol was transferred from L-CD to the £uorosome
membrane in the second experiment.
In conclusion, the Fluorosome technique should prove val-
uable in the design, characterization, and development of drug
delivery systems. It has the potential to provide a simple,
sensitive in vitro means, at an early phase of development,
for characterizing the ability of drug delivery vehicles to re-
lease molecules into membranes or extract them from mem-
branes.
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